The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Sitagliptin/Metformin hydrochloride Rowa 50 mg/850 mg film-coated tablets

Rowa Pharmaceuticals LimitedPA0074/090/001

Main Information

Trade NameSitagliptin/Metformin hydrochloride Rowa 50 mg/850 mg film-coated tablets
Active SubstancesMetformin Hydrochloride
Sitagliptin Hydrochloride Monohydrate
Dosage FormFilm-coated tablet
Licence HolderRowa Pharmaceuticals Limited
Licence NumberPA0074/090/001

Group Information

ATC CodeA10BD07 metformin and sitagliptin


License statusAuthorised
Licence Issued22/04/2022
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusMarketed


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available

Generics Information

Interchangeable List CodeIC0070-121-003
Interchangeable List DocumentPDF of Interchangeable List
« Back